Scynexis (SCYX) Stock
Small biotech company developing antifungal medicines. Here's the price, business snapshot, and what's worth knowing about Scynexis in October 2026.
SCYNEXIS Inc (SCYX) is a small-cap biotechnology company focused on developing novel antifungal therapies. With a market capitalisation of about $32.7 million, it is a relatively small, specialised issuer where clinical progress and regulatory milestones tend to drive valuation. Investors should note the typical biotech risk profile: research and development outcomes, trial results and approvals can materially affect the share price, while revenues may be limited or intermittent. SCYNEXIS’s work centres on antifungal medicines addressing unmet needs; success would depend on clinical efficacy, safety, reimbursement and commercial execution. The company can appeal to investors seeking exposure to specialty infectious-disease science, but it is more suitable for those comfortable with higher volatility, long development timelines and binary news events. This summary provides general educational information only and is not personal financial advice — consider your objectives and seek professional guidance before investing.
Scynexis (SCYX) Stock Forecast
Analyst price target, next 12 months
$24.20
+372.7% vs today's $5.12
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Scynexis have a consensus 12-month target of $24.20, above the current price of $5.12.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 28 Aug 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying SCYNEXIS's stock with a target price of $24.2, indicating strong potential growth.
Financial Health
SCYNEXIS INC shows solid revenue and cash flow, indicating a healthy operational performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Pipeline-Driven Value
Company value is heavily influenced by clinical and regulatory milestones, which can create rapid share movement — though outcomes are uncertain.
Specialist Therapeutics
Focus on antifungal treatments targets an underserved area of infectious disease, but commercial uptake and reimbursement are not guaranteed.
Catalysts To Watch
Key catalysts include trial results, approvals and partnerships; monitor cash runway and financing as they affect execution risk.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
